TOPLINE:
Short-term use of continuous glucose monitoring (CGM) provided valuable insights into lifestyle factors affecting blood glucose levels in people with type 2 diabetes (T2D) who were not on insulin therapy, particularly in those with a diabetes duration of less than 5 years.
METHODOLOGY:
- CGM is an effective strategy for managing blood glucose levels in people with non-insulin-treated T2D; this study focused on the insights gained regarding lifestyle factors affecting blood glucose levels over a 2-week period of usage.
- Participants with non-insulin-treated T2D across 20 cities in Denmark received a single CGM device during a walk-in setup, with minimal guidance provided during device installation.
- They used the CGM device for a maximum of 14 days.
- Baseline questionnaires were completed onsite, with follow-up surveys sent via email after 2 weeks and after 3 months.
TAKEAWAY:
- A total of 724 participants completed the second questionnaire sent after 2 weeks.
- Of these, 80% found CGM highly useful and informative for managing T2D.
- Participants with a diabetes duration of less than 5 years engaged in more daily scans (80% vs 71%) and reported greater insights into the effects of lifestyle on glucose levels — including food (88% vs 78%), portion sizes (80% vs 60%), and physical activity (65% vs 55%) — than those with a diabetes duration of more than 5 years.
- Education level did not significantly affect the knowledge gained from CGM usage.
- At the 3-month follow-up, 50% of participants reported maintaining behavioral changes based on their CGM experience.
IN PRACTICE:
“These insights may encourage long-term behavioral changes, potentially leading to improved glycemic control,” the authors wrote.
SOURCE:
The study was led by Emma Munch Nielsen, Glostrup, Denmark. It was presented by Tanja Thybo, Glostrup, Denmark, on June 20, 2025, at the 85th Scientific Sessions – American Diabetes Association, held at the McCormick Place Convention Center, Chicago.
LIMITATIONS:
No limitations were discussed in the abstract.
DISCLOSURES:
No funding details were disclosed. Three authors disclosed relationships with Abbott.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.